How Long Do Peptides Take to Work? A Realistic Timeline by Compound
Most people give up on a compound before it could possibly have worked. Two weeks in, nothing obvious has happened, and the conclusion is that it isn't working — when the honest answer is that almost nothing in this category shows meaningful change in two weeks. This guide gives realistic timelines drawn from actual trial data, explains why some effects arrive in an hour and others take six months, and is straight about the compounds where nobody actually knows.
The one thing that explains every timeline
Here's the principle that makes all of this make sense: the clock is set by the biology of what you're measuring, not by the compound.
A molecule that binds a brain receptor can change how you feel within the hour, because the receptor is right there and the signal is immediate. A molecule that changes body composition has to work through weeks of altered energy balance. A molecule that rebuilds tendon has to wait for collagen turnover, which happens on a timescale of months regardless of what you do.
Nothing speeds that up. A tendon does not remodel faster because you took a stronger compound — it remodels at the rate tendons remodel.
So the useful question is never "how fast does this peptide work." It's "how fast does the thing I'm hoping changes change." Once you know that, the timeline stops being mysterious.
Four speeds, four kinds of biology
| Speed | What's changing | Examples |
|---|---|---|
| Hours | Direct receptor signalling in the brain | PT-141 and arousal pathways |
| Days to weeks | Blood markers, appetite signalling, sleep architecture | IGF-1 levels, GLP-1 appetite effects, GH secretagogues and sleep |
| Weeks to months | Fat mass, body composition, skin quality | Weight loss, visceral fat, skin elasticity |
| Many months | Structural tissue turnover | Tendon, cartilage, hair, bone |
Notice that most of what people actually want sits in the bottom two rows. That's the mismatch — expectations are set by the top row and reality lives at the bottom.
Hours: the fast one
PT-141 (bremelanotide) is the outlier in this entire category, and it's fast because of what it does: it activates melanocortin receptors in the central nervous system directly, rather than changing anything structural.
- Onset: roughly 30–60 minutes after subcutaneous injection
- Peak: around 2–4 hours
- Duration: commonly 6–12 hours, with some reports considerably longer
- Half-life: about 2.7 hours
It's used on demand rather than continuously, which is unusual here — essentially everything else in this article is a cumulative-effect compound.
Worth noting: nausea is the most common effect reported in trials, and it shows up in the same window as the intended effect rather than after it.
Days to weeks: markers and signals
GLP-1 compounds and appetite
With semaglutide, tirzepatide and retatrutide, the appetite change is the early signal. Most people notice reduced hunger and earlier fullness within the first week or two — often described as food simply becoming less interesting.
That's not weight loss. It's the mechanism that produces weight loss over the following months. Confusing the two is where a lot of disappointment comes from.
Growth hormone secretagogues and sleep
With sermorelin, ipamorelin and CJC-1295, sleep quality is typically the first thing people report, usually within the first few weeks. There's a plausible mechanism — growth hormone release is concentrated in deep sleep, and the research literature does describe sleep quality improvements with compounds that raise GH within physiological range.
Be a little careful with this one. Sleep is highly susceptible to expectation, and it's the first thing people notice partly because it's the first thing they're watching for.
Blood markers
IGF-1 responds fastest of anything measurable. In the pivotal tesamorelin trial, IGF-1 rose roughly 81% above baseline by week 26 — but the rise begins within days, not months. If you're tracking bloodwork, this is the marker that moves early and confirms the compound is doing something biochemically, well before anything is visible.
Weeks to months: body composition
This is where most goals actually live, and where the trial data is clearest.
Weight loss on GLP-1s
The pivotal trials ran 68 to 72 weeks. That's not a formality — it's how long the effect took to fully develop.
- Semaglutide (STEP 1): 14.9% average weight reduction at 68 weeks
- Tirzepatide (SURMOUNT-1): 20.9% at 72 weeks on the top dose
- Long-term: in the four-year SELECT follow-up, weight loss continued for roughly 65 weeks before levelling off, then held steady through 208 weeks
Meaningful loss is usually visible by months 2–3, but the curve keeps going for well over a year. Judging results at week 6 tells you almost nothing.
Visceral fat on tesamorelin
Tesamorelin has the most precisely defined timeline of any compound here, because regulators put a number on it.
- 26 weeks is the trial endpoint. Visceral adipose tissue fell 10.9% versus 0.6% on placebo in the pivotal NEJM trial of 412 patients
- A pooled analysis of 806 patients found roughly 15.4% VAT reduction at 26 weeks, sustained through 52 weeks
- A 12-month trial found a net 19% VAT reduction versus placebo
The most useful single fact in this article: the FDA label instructs that if trunk fat has not decreased after 26 weeks, treatment should be discontinued. That's a regulator formally defining how long to give a compound before concluding it isn't working — six months. It's a reasonable benchmark to borrow for thinking about body-composition compounds generally.
Skin
For GHK-Cu, human facial skin trials have reported around a 22% increase in firmness and 16% reduction in fine lines — with results plateauing around week 10. Collagen peptide trials generally show hydration shifting around week 4 and elasticity taking 12 weeks or more.
Many months: structural tissue
Some tissues simply turn over slowly, and no compound changes that.
Hair is the clearest example. The growth phase lasts years and the resting phase around three months, so nothing can produce visible change quickly — hair treatment trials typically measure at 4–6 months minimum. Early shedding after starting a treatment is often follicles resetting rather than a failure.
Tendon, ligament and cartilage are slower still. Collagen turnover in these tissues runs on a scale of months to years. Joint outcome trials are typically assessed at 90–180 days, and that's for symptom change rather than structural repair.
Bone is the slowest of all — remodelling cycles take months per site.
If your goal sits in this group, a three-month evaluation window is the minimum that means anything, and six is more honest.
Quick reference by compound
| Compound | First signal | Meaningful change | Evidence quality |
|---|---|---|---|
| PT-141 | 30–60 minutes | Same session | Strong — FDA approved |
| Semaglutide | Appetite, 1–2 weeks | 68 weeks in trials | Strong |
| Tirzepatide | Appetite, 1–2 weeks | 72 weeks in trials | Strong |
| Tesamorelin | IGF-1 within days | 26 weeks (label benchmark) | Strong |
| Sermorelin / Ipamorelin / CJC-1295 | Sleep, 2–4 weeks | Body composition, 2–3 months | Limited — mostly extrapolated from tesamorelin |
| GHK-Cu (skin) | 4–6 weeks | Plateau around week 10 | Moderate |
| Collagen peptides | Hydration, ~4 weeks | Elasticity, 12+ weeks | Moderate |
| MT-II (pigmentation) | Days to weeks | Weeks, cumulative | Limited |
| BPC-157 | No human data | Unknown | Preclinical only |
| TB-4 / TB-500 | No human data | Unknown | Preclinical only |
| Epithalon | No human data | Unknown | Very limited |
Why side effects arrive before benefits
This is the part nobody warns people about, and it's the main reason protocols get abandoned in week three.
Side effects follow drug concentration. Benefits follow biological change. Concentration peaks within hours of a dose. Biological change takes weeks to months. So the unpleasant part arrives first, reliably, while the reason you started is still forming.
With GLP-1 compounds this is well documented: digestive effects peak in the first two to four weeks after starting and after each dose increase, then fade as the body adapts. Pooled trial data puts the median nausea episode at roughly 8 to 14 days.
Which means that at week three — feeling queasy, nothing visible on the scale — you're at the exact point of maximum discomfort and minimum reward. It feels like evidence that it isn't working. It's actually the normal shape of the curve.
The titration trap
Here's something easy to miss: with compounds that escalate in steps, you spend the first weeks below a therapeutic dose on purpose.
Semaglutide takes 16 weeks to reach the 2.4 mg maintenance dose. Tirzepatide steps up in 2.5 mg increments at four-week intervals. Those opening doses are tolerance steps, not treatment doses — they exist so the digestive system can adapt.
So someone at week 6 who feels nothing much isn't experiencing a failure. They're two-thirds of the way through a ramp that hasn't reached its destination.
Add the titration period to the biological timeline and the picture clarifies: four months from starting to a fair assessment is normal for this class, not slow.
The compounds where nobody actually knows
For several popular research compounds, any timeline you read online is invented. Not exaggerated — invented, because the underlying human data doesn't exist.
BPC-157 has extensive animal research and, as of a 2025 systematic review covering 36 studies, no completed controlled human efficacy trials. TB-4 is similar — a 2026 scoping review of 80 studies found direct human evidence on the fragment amounted to essentially nothing. Epithalon and several other longevity compounds are in the same position.
When a page tells you "expect results from BPC-157 in 2–4 weeks," that number came from forum consensus, not from a trial. It might be roughly right. There's no way to know, and presenting it as established is dishonest.
What we can say: animal healing studies typically run weeks rather than days, and human tissue repair operates on a slower timescale than rodent tissue repair. Beyond that, the accurate answer is that it's unknown — and blends like KLOW and GLOW inherit that uncertainty from their components.
How to tell whether something is actually working
The hardest part of a long timeline is that gradual change is invisible day to day. A few things genuinely help.
Set your evaluation date before you start. Decide in advance when you'll assess — 12 weeks, 26 weeks — and don't re-evaluate constantly in between. Continuous assessment produces noise, not information.
Measure the thing you care about, not the thing that's easy. Body weight is easy and often the wrong metric. Tesamorelin's whole case rests on visceral fat, which barely moves the scale. Waist circumference, photographs under consistent conditions, strength numbers and bloodwork all carry more signal.
Take a baseline. Photos, measurements, labs — before, not three weeks in. Almost everyone regrets not having one.
Change one thing at a time. Starting three compounds together means learning nothing about any of them.
Expect the first month to be misleading in both directions. Early enthusiasm and early disappointment are both mostly noise.
When to stop waiting
Patience isn't infinite, and "give it more time" can become a way of avoiding an answer.
Reasonable stopping points, based on how these compounds behave:
- Appetite-driven compounds: if there's no appetite change at all once you've reached a maintenance dose, that's informative. The mechanism should be noticeable.
- Body composition: 26 weeks is the benchmark regulators applied to tesamorelin, and it's a sensible ceiling for this category generally.
- Skin: 12 weeks. The GHK-Cu data plateaus around week 10, so little new is arriving after that.
- Structural tissue: 3–6 months minimum before any conclusion is meaningful.
Stop sooner than any of these if something is wrong — persistent side effects, an unexpected reaction, or anything that concerns you. There's no timeline that makes pushing through a genuine problem sensible.
Get the basics right first
Timelines only mean something if handling and preparation are correct. Our calculator handles reconstitution, and every batch we supply is third-party tested with results published openly.
View the COA databaseFrequently asked questions
How long before I notice anything?
It depends entirely on the mechanism. PT-141 acts within 30–60 minutes. GLP-1 appetite changes appear in one to two weeks. Sleep changes on GH secretagogues are usually reported within a few weeks. Body composition takes months, and structural tissue takes longer still.
I've been taking it three weeks and nothing's happened. Is it working?
Three weeks is too early for almost everything except the fastest-acting compounds. If you're on a titration schedule you may not have reached a therapeutic dose yet — semaglutide takes 16 weeks to reach maintenance. Four months from starting to a fair assessment is normal for this class.
Why do I feel worse before I feel better?
Side effects track drug concentration, which peaks within hours. Benefits track biological change, which takes weeks to months. So the unpleasant part arrives first. With GLP-1s, digestive effects peak in the first two to four weeks and after each dose increase, with the median nausea episode lasting 8 to 14 days.
How long does tesamorelin take to reduce visceral fat?
The trials measured at 26 weeks, finding roughly 10.9% to 15.4% visceral fat reduction versus placebo. The FDA label instructs discontinuation if trunk fat hasn't decreased after 26 weeks — making six months the formal benchmark for whether it's working.
How long does BPC-157 take to work?
Nobody knows. A 2025 systematic review covering 36 studies found no completed controlled human efficacy trials, so no reliable human timeline exists. Any specific number you see online comes from forum consensus rather than data.
Do results keep improving or plateau?
Varies. GHK-Cu skin results plateau around week 10. GLP-1 weight loss continues for roughly 65 weeks before levelling off, then holds steady through four years. Tesamorelin's visceral fat reduction is sustained through 52 weeks. A plateau usually means a new equilibrium rather than a compound losing effect.
Does taking more make it faster?
Generally no, and it reliably increases side effects. Titration schedules exist because tolerability, not impatience, sets the pace — and tissue biology doesn't accelerate with dose. Compressing a ramp mostly buys a worse experience.
The bottom line
Almost every disappointment in this category comes from a mismatch between expectation and biology. People expect weeks and the honest answer is months, because the tissue being changed turns over on a monthly scale no matter what's driving it.
The realistic version: hours for direct receptor effects, one to two weeks for appetite and sleep signals, two to three months before body composition changes are convincing, six months before a fair verdict on most goals, and longer for anything structural.
Set an evaluation date before you start. Take a baseline. Then leave it alone until you get there — because the single most common mistake here isn't choosing the wrong compound, it's quitting a reasonable one at week three.
For compound-specific detail, our Info Center covers each individually, and the reconstitution calculator handles preparation.
This article is provided for educational and informational purposes only. It is not medical advice, and it is not intended to diagnose, treat, cure or prevent any condition. Timelines described here are drawn from published clinical trial data where it exists and are clearly identified where it does not; individual responses vary considerably. Anyone using a prescribed medicine should follow the guidance of their prescriber. Products offered by Peptides Costa Rica are intended strictly for laboratory research use only. They are not approved or licensed by the FDA for the prevention, diagnosis, treatment or cure of any disease. Not for human or veterinary use.
